Matching your innovation goals with grant opportunities
Gelexir Healthcare Limited is a UK based biomedical company that is introducing a novel, non-surgical procedure for the treatment of Chronic Lower Back Pain (CLBP) caused by Degenerative Disc Disease (DDD).
Gelexir’s novel approach addresses DDD at an early stage before the onset of irreversible disc degeneration of both the nucleus pulposus and annulus fibrosis material.
Gelexir approached Trove Associates whilst seeking funding for the latter stages of this medical device’s development pathway. Trove’s actions resulted in securing a Grant of £250,000 through Innovate UK’s Development of Prototype SMART award.
Quote: “We selected Trove as they presented a unique understanding of the requirement to make a bridge between the Grantor and Assessors’ criteria for a particular funding scheme, and our overall company goals. They were very effective in presenting our Project in a way that showed clear alignment with the Grantor’s objectives.”
Dr. Philippe Jenny, CEO of Gelexir Healthcare Limited